The high binding affinity of the synthetic octapeptide analogs to SSTR in malignant pediatric samples suggests that children with SSTR-positive cancers might be good candidates for therapy with SST analogs, including the targeted cytotoxic SST analog AN-162. The gene discussed is SST; the disease is cancer.